naa a22 4500 510763723 CHVBK 20180411083149.0 cr unu---uuuuu 180411e20130301xx s 000 0 eng 10.1007/s12094-012-0903-2 doi (NATIONALLICENCE)springer-10.1007/s12094-012-0903-2 Decreased expression of chromodomain helicase DNA-binding protein 5 is an unfavorable prognostic marker in patients with primary gallbladder carcinoma [Elektronische Daten] [Xilin Du, Tao Wu, Jianguo Lu, Li Zang, Nuan Song, Tao Yang, Huadong Zhao, Shengzhi Wang] Aim: Chromodomain helicase DNA-binding protein 5 (CHD5) plays a role in normal neural development and in tumorigenesis of various human cancers. However, its role in primary gallbladder carcinoma (PGC) is still unclear. The aim of this study was to investigate CHD5 expression in PGC and its clinical significance. Methods: CHD5 mRNA and protein expression in 120 PGC and 20 normal gallbladder specimens was determined by quantitative reverse transcription-polymerase chain reaction (QRT-PCR) and Western blotting analysis, respectively. Results: The expression levels of CHD5 mRNA and protein in PGC tissues were both significantly lower than those in the normal epithelium of the gallbladder (mRNA: P=0.006; protein: P=0.01). CHD5 mRNA expression was closely correlated with its protein expression (r=0.8; P<0.001). Additionally, the low expression of CHD5 protein was significantly associated with high pathologic T stage (P=0.01) and clinical stage (P=0.008), and advanced histologic grade (P=0.009). The expression levels of CHD5 protein in PGC tissues with positive nodal metastasis were also significantly lower than those without (P=0.01). Survival analysis showed that low CHD5 expression was associated with shorter disease-free (P=0.01) and overall survival (P=0.008) compared to those with high CHD5 expression in PGC patients. Furthermore, multivariate analyses showed that the decreased expression of CHD5 was an independent prognostic marker for both unfavorable disease-free (P=0.01) and overall survival (P=0.006). Conclusion: CHD5 may be involved in carcinogenesis of PGC and its down-regulation may be significantly correlated with unfavorable clinicopathologic features including poor overall and disease-free survival in patients. Federación de Sociedades Españolas de Oncología (FESEO), 2012 Primary gallbladder carcinoma nationallicence Chromodomain helicase DNA-binding protein 5 nationallicence Clinicopathology nationallicence Overall survival nationallicence Disease-free survival nationallicence Du Xilin Department of General Surgery, Tangdu Hospital, Fourth Military Medical University, 710038, Xi'an, People's Republic of China aut Wu Tao Department of General Surgery, Tangdu Hospital, Fourth Military Medical University, 710038, Xi'an, People's Republic of China aut Lu Jianguo Department of General Surgery, Tangdu Hospital, Fourth Military Medical University, 710038, Xi'an, People's Republic of China aut Zang Li Department of General Surgery, Tangdu Hospital, Fourth Military Medical University, 710038, Xi'an, People's Republic of China aut Song Nuan Department of General Surgery, Tangdu Hospital, Fourth Military Medical University, 710038, Xi'an, People's Republic of China aut Yang Tao Department of General Surgery, Tangdu Hospital, Fourth Military Medical University, 710038, Xi'an, People's Republic of China aut Zhao Huadong Department of General Surgery, Tangdu Hospital, Fourth Military Medical University, 710038, Xi'an, People's Republic of China aut Wang Shengzhi Department of General Surgery, Tangdu Hospital, Fourth Military Medical University, 710038, Xi'an, People's Republic of China aut Clinical and Translational Oncology Springer Milan 15/3(2013-03-01), 198-204 1699-048X 15:3<198 2013 15 12094 https://doi.org/10.1007/s12094-012-0903-2 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0903-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Du Xilin Department of General Surgery, Tangdu Hospital, Fourth Military Medical University, 710038, Xi'an, People's Republic of China aut NATIONALLICENCE 700 1- Wu Tao Department of General Surgery, Tangdu Hospital, Fourth Military Medical University, 710038, Xi'an, People's Republic of China aut NATIONALLICENCE 700 1- Lu Jianguo Department of General Surgery, Tangdu Hospital, Fourth Military Medical University, 710038, Xi'an, People's Republic of China aut NATIONALLICENCE 700 1- Zang Li Department of General Surgery, Tangdu Hospital, Fourth Military Medical University, 710038, Xi'an, People's Republic of China aut NATIONALLICENCE 700 1- Song Nuan Department of General Surgery, Tangdu Hospital, Fourth Military Medical University, 710038, Xi'an, People's Republic of China aut NATIONALLICENCE 700 1- Yang Tao Department of General Surgery, Tangdu Hospital, Fourth Military Medical University, 710038, Xi'an, People's Republic of China aut NATIONALLICENCE 700 1- Zhao Huadong Department of General Surgery, Tangdu Hospital, Fourth Military Medical University, 710038, Xi'an, People's Republic of China aut NATIONALLICENCE 700 1- Wang Shengzhi Department of General Surgery, Tangdu Hospital, Fourth Military Medical University, 710038, Xi'an, People's Republic of China aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/3(2013-03-01), 198-204 1699-048X 15:3<198 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer